JP2023527422A - ＳＡＲＳ－ＣｏＶ－２感染を予防および治療するための組成物および方法 - Google Patents

ＳＡＲＳ－ＣｏＶ－２感染を予防および治療するための組成物および方法 Download PDF

Info

Publication number
JP2023527422A
JP2023527422A JP2022573297A JP2022573297A JP2023527422A JP 2023527422 A JP2023527422 A JP 2023527422A JP 2022573297 A JP2022573297 A JP 2022573297A JP 2022573297 A JP2022573297 A JP 2022573297A JP 2023527422 A JP2023527422 A JP 2023527422A
Authority
JP
Japan
Prior art keywords
subject
lactoferrin
pharmaceutical composition
cells
cov
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022573297A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023527422A5 (enExample
Inventor
ゼット． セックストン，ジョナサン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Michigan System
University of Michigan Ann Arbor
Original Assignee
University of Michigan System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Michigan System filed Critical University of Michigan System
Publication of JP2023527422A publication Critical patent/JP2023527422A/ja
Publication of JP2023527422A5 publication Critical patent/JP2023527422A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
JP2022573297A 2020-05-28 2021-05-26 ＳＡＲＳ－ＣｏＶ－２感染を予防および治療するための組成物および方法 Pending JP2023527422A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063031310P 2020-05-28 2020-05-28
US63/031,310 2020-05-28
PCT/US2021/034234 WO2021242850A1 (en) 2020-05-28 2021-05-26 Compositions and methods for preventing and treating sars-cov-2 infection

Publications (2)

Publication Number Publication Date
JP2023527422A true JP2023527422A (ja) 2023-06-28
JP2023527422A5 JP2023527422A5 (enExample) 2024-06-21

Family

ID=78722710

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022573297A Pending JP2023527422A (ja) 2020-05-28 2021-05-26 ＳＡＲＳ－ＣｏＶ－２感染を予防および治療するための組成物および方法

Country Status (4)

Country Link
US (1) US20240016901A1 (enExample)
EP (1) EP4157327A4 (enExample)
JP (1) JP2023527422A (enExample)
WO (1) WO2021242850A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12450735B2 (en) * 2021-09-02 2025-10-21 Memorial Sloan-Kettering Cancer Center Learning representations of nuclei in histopathology images with contrastive loss
EP4148042A1 (en) * 2021-09-10 2023-03-15 Centre National de la Recherche Scientifique Phenoxy-acetyl-thioureido-benzenesulfonamide derivatives, and their uses
WO2023147186A2 (en) * 2022-01-31 2023-08-03 Kotlyar David Transgenic seeds for inhibiting viral replication via anticommunicable fortification system (acf system) with concomitant method of treatment or prevention of viral disease, and pandemic prevention and elimination
CN116115611A (zh) * 2022-11-07 2023-05-16 靖江市人民医院 甲磺酸洛美他派在制备抑制新型冠状病毒的产品中的应用
WO2025245059A1 (en) * 2024-05-23 2025-11-27 Yale University Compositions comprising gsk-3 and/or beta-catenin inhibitors and/or degraders and methods of use thereof
CN121227875B (zh) * 2025-11-26 2026-04-10 内蒙古医科大学附属医院(内蒙古自治区心血管研究所) 一种抗病毒药物筛选标志物、微粒体甘油三酯转移蛋白抑制剂在制备抗病毒药物中的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050075277A1 (en) * 2003-07-10 2005-04-07 Agennix Incorporated Use of lactoferrin in prophylaxis against infection and/or inflammation in immunosuppressed subjects
CN101715349B (zh) * 2007-05-08 2012-07-18 美国Rq生物科技有限公司 治疗革兰氏阴性细菌感染的治疗组合物及方法
US20170296530A1 (en) * 2012-07-03 2017-10-19 Justice E. OBI Compositions and Methods for Treating and Inhibiting Viral Infections
WO2014122537A2 (en) * 2013-02-05 2014-08-14 Genoscience Sa Pharmaceutical compositions and methods of treating hepatitis c virus infection using a combination of hydroxychloroquine and ribavirin
AU2014310935B2 (en) * 2013-08-21 2019-11-21 CureVac SE Combination vaccine
KR20230156963A (ko) * 2014-10-07 2023-11-15 엠와이알 게엠베하 Hbv 및 hdv 감염의 조합 치료법
TW201919675A (zh) * 2017-09-07 2019-06-01 德商艾庫瑞斯公司 使用羊副痘疹病毒(Parapoxvirus ovis；PPVO)及至少一種額外抗病毒藥之經B型肝炎病毒(HBV)感染之個體之組合療法
CN111097040A (zh) * 2020-02-19 2020-05-05 苟春虎 抗病毒清肺肽
IT202000005026A1 (it) * 2020-03-09 2021-09-09 Sofar Spa Lattoferrina per uso inalatorio ad azione antivirale
IT202000005011A1 (it) * 2020-03-09 2021-09-09 Sofar Spa Lattoferrina per uso orale ad azione antivirale
GB2593452A (en) * 2020-03-16 2021-09-29 Mead Johnson Nutrition Co Use of lactoferrin
US20230149515A1 (en) * 2020-04-29 2023-05-18 The Regents Of The University Of Michigan Inhibition of sars-cov-2 viral entry through oral administration of lactoferrin and uses thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
COMPTES RENDUS BIOLOGIES, vol. 337, JPN6025022893, 2014, pages 581 - 595, ISSN: 0005743398 *
INTERNATIONAL JOURNAL OF RESEARCH IN HEALTH SCIENCES, vol. Vol.8, Issue 1, JPN6025022892, 22 April 2020 (2020-04-22), pages 8 - 15, ISSN: 0005743399 *
医薬品インタビューフォーム バラクルード錠 0.5MG, vol. 2019年5月（第9版）, JPN6025022891, 2019, pages 1 - 74, ISSN: 0005743400 *

Also Published As

Publication number Publication date
EP4157327A4 (en) 2024-11-27
US20240016901A1 (en) 2024-01-18
EP4157327A1 (en) 2023-04-05
WO2021242850A1 (en) 2021-12-02

Similar Documents

Publication Publication Date Title
JP2023527422A (ja) ＳＡＲＳ－ＣｏＶ－２感染を予防および治療するための組成物および方法
US20240261307A1 (en) Inhibitors of sars-cov-2 viral replication and uses thereof
WO2021234097A1 (en) Mek-inhibitors for the treatment or prevention of coronavirus infections and/or covid-19 cytokine storm
EP4146192A1 (en) Methods and compositions for the treatment of sars-cov-2
Booth et al. AR‐12 inhibits multiple chaperones concomitant with stimulating autophagosome formation collectively preventing virus replication
Wang et al. Inhibition of aberrant cyclin-dependent kinase 5 activity attenuates isoflurane neurotoxicity in the developing brain
Milbradt et al. Sensitivity of human herpesvirus 6 and other human herpesviruses to the broad-spectrum antiinfective drug artesunate
US20170304293A1 (en) Coordinated metabolic reprogramming in response to productive viral infections
Li et al. Ginsenoside Rg1 alleviates learning and memory impairments and Aβ disposition through inhibiting NLRP1 inflammasome and autophagy dysfunction in APP/PS1 mice
Kumar et al. The chronicle of COVID-19 and possible strategies to curb the pandemic
CN113768917A (zh) 木犀草素在抑制nlrp3炎症小体活化中的应用
Marim et al. Inhibition of tryptophan catabolism is associated with neuroprotection during zika virus infection
WO2018025923A1 (ja) 抗ｈｔｌｖ－１剤、ｈｔｌｖ－１関連脊髄症（ｈａｍ／ｔｓｐ）治療薬
WO2023023469A1 (en) Inhibitors for coronavirus
US20170360784A1 (en) Trizol-1-ol analogs anti-retroviral latency drugs
Sadhu et al. Fangchinoline inhibits SARS-CoV-2 and MERS-CoV entry
Wang et al. Effectiveness of nucleoside analogs against Wetland virus infection
JP2023522689A (ja) ＣｏＶ－２２９Ｅ又はＣｏＶ－ＯＣ４３コロナウイルス感染症の治療において使用される４－（３－（ピリジン－３－イル）ピラゾロ［１，５－ａ］ピリミジン－５－イル）ピペラジン
Wang et al. Fangchinoline induces antiviral response by suppressing STING degradation
Kaushik et al. Glycolytic stress deteriorates 229E virulence to improve host defense response
Belouzard et al. Large scale screening discovers clofoctol as an inhibitor of SARS-CoV-2 replication that reduces COVID-19-like pathology
Jia et al. Recent advances of phenotypic screening strategies in the application of anti-influenza virus drug discovery
EP2838903B1 (en) Methods and compositions for treating viral infections
Zhou et al. Clofazimine targeting the spike protein and RdRp exhibits highly efficient antiviral activity against porcine epidemic diarrhea virus in vitro
Ma et al. Antiviral effectiveness of Sarcandra glabra and Fragaria vesca extracts against influenza A H1N1

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240527

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240527

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240612

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250610

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20251202